Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02454478
- Locations
- 🇯🇵
Eisai Trial Site #1, Tokyo, Japan
🇯🇵Eisai Trial Site #2, Tokyo, Japan
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 117
- Registration Number
- NCT02432274
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇫🇷Centre Oscar Lambret Lille, Lille, Rhone, France
🇫🇷CHU de Toulouse - Hopital des Enfants, Toulouse, France
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 629
- Registration Number
- NCT02430714
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02421042
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
- Conditions
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT02211222
A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02199379
A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02199392
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
- Conditions
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01877083
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬National Cancer Center Hospital, Singapore, Singapore
🇨🇳Veterans General Hospital Taipei, Taipei, Taiwan
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 954
- Registration Number
- NCT01761266
- Locations
- 🇬🇧
Facility # 3, London, Greater London, United Kingdom
🇬🇧Facility # 2, London, Greater London, United Kingdom
🇰🇷Facility # 6, Seoul, Korea, Republic of
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
- Conditions
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT01529112
- Locations
- 🇧🇪
C. H. R. de la Citadelle, Liege, Belgium
🇭🇺Tudogyogyintezet Torokbalint, Torokbalint, Hungary
🇭🇺Fejer Megyei Szent Gyorgy Korhaz, Szekesfehervar, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.